Trial Profile
A study to evaluate the safety and efficacy of Basiliximab in de novo heart transplant recipients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Oct 2017
Price :
$35
*
At a glance
- Drugs Basiliximab (Primary)
- Indications Heart transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 19 Oct 2017 New trial record
- 09 Oct 2017 Results published in the Clinical Transplantation